Technology Insight: vaccine therapy for prostate cancer
Johannes Vieweg* and Jens Dannull
Correspondence *Duke University Medical Center, MSRB, Suite 455, PO Box 2626, Research Drive, Durham, North Carolina 27710, USA
Email j.vieweg@duke.edu
Despite the amount of research that has gone into producing vaccines against cancer, these vaccines have yet to show clinical benefit. This article by J Vieweg and J Dannull reviews the current status of vaccination strategies for prostate cancer, and gives an update on the different stages in their development.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Cancer vaccine strategies get bigger and betterNature Medicine News and Views (01 Oct 1999)
RESEARCH
Metalloproteases regulate T-cell proliferation and effector function via LAG-3The EMBO Journal Article (24 Jan 2007)
See all 26 matches for Research